Li Yuze, Wang Zhe, Ma Shengyao, Tang Xiaowen, Zhang Hanting
Department of Pharmacology, School of Pharmacy, Qingdao University, Qingdao 266071, China.
Shandong Provincial Key Laboratory of Pathogenesis and Prevention of Brain Diseases, Qingdao University, Qingdao 266071, China.
Pharmaceuticals (Basel). 2025 Mar 21;18(4):444. doi: 10.3390/ph18040444.
: Phosphodiesterase 7 (PDE7), a member of the PDE superfamily, selectively catalyzes the hydrolysis of cyclic adenosine 3',5'-monophosphate (cAMP), thereby regulating the intracellular levels of this second messenger and influencing various physiological functions and processes. There are two subtypes of PDE7, PDE7A and PDE7B, which are encoded by distinct genes. PDE7 inhibitors have been shown to exert therapeutic effects on neurological and respiratory diseases. However, FDA-approved drugs based on the PDE7A inhibitor are still absent, highlighting the need for novel compounds to advance PDE7A inhibitor development. : To address this urgent and important issue, we conducted a comprehensive cheminformatics analysis of compounds with potential for PDE7A inhibition using a curated database to elucidate the chemical characteristics of the highly active PDE7A inhibitors. The specific substructures that significantly enhance the activity of PDE7A inhibitors, including benzenesulfonamido, acylamino, and phenoxyl, were identified by an interpretable machine learning analysis. Subsequently, a machine learning model employing the Random Forest-Morgan pattern was constructed for the qualitative and quantitative prediction of PDE7A inhibitors. : As a result, six compounds with potential PDE7A inhibitory activity were screened out from the SPECS compound library. These identified compounds exhibited favorable molecular properties and potent binding affinities with the target protein, holding promise as candidates for further exploration in the development of potent PDE7A inhibitors. : The results of the present study would advance the exploration of innovative PDE7A inhibitors and provide valuable insights for future endeavors in the discovery of novel PDE inhibitors.
磷酸二酯酶7(PDE7)是磷酸二酯酶超家族的成员,可选择性催化3',5'-环磷酸腺苷(cAMP)的水解,从而调节这种第二信使的细胞内水平,并影响各种生理功能和过程。PDE7有两种亚型,PDE7A和PDE7B,由不同的基因编码。PDE7抑制剂已显示出对神经和呼吸系统疾病的治疗作用。然而,目前仍没有美国食品药品监督管理局(FDA)批准的基于PDE7A抑制剂的药物,这凸显了开发新型化合物以推进PDE7A抑制剂研发的必要性。
为了解决这一紧迫且重要的问题,我们使用一个经过整理的数据库,对具有PDE7A抑制潜力的化合物进行了全面的化学信息学分析,以阐明高活性PDE7A抑制剂的化学特征。通过可解释的机器学习分析,确定了显著增强PDE7A抑制剂活性的特定亚结构,包括苯磺酰胺基、酰氨基和苯氧基。随后,构建了一个采用随机森林-摩根指纹图谱的机器学习模型,用于定性和定量预测PDE7A抑制剂。
结果,从SPECS化合物库中筛选出了六种具有潜在PDE7A抑制活性的化合物。这些鉴定出的化合物表现出良好的分子性质和与靶蛋白的强结合亲和力,有望作为进一步探索强效PDE7A抑制剂的候选物。
本研究结果将推进新型PDE7A抑制剂的探索,并为未来发现新型磷酸二酯酶抑制剂的努力提供有价值的见解。